IP Library Granted Patent US 8,158,424
Granted Patent B2
US 8,158,424 · App. 12/754,574 · Granted Apr 17, 2012

Primate pluripotent stem cells cultured in medium containing gamma-aminobutyric acid, pipecolic acid and lithium

Assignee: Wisconsin Alumni Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,424
App. No.
12/754,574
Granted
Apr 17, 2012
Kind
B2
Abstract

Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.

Claims (25)

1. A method for culturing primate pluripotent stem cells in an undifferentiated state on a matrix without the need for feeder cells or conditioned medium, the method comprising the step of:

culturing the primate pluripotent stem cells on an extracellular matrix in a medium without feeder cells or conditioned media, the medium comprising salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium in sufficient amounts to maintain the cells in an undifferentiated state through multiple successive culture passages.

2. The method of claim 1 wherein the matrix comprises a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma or a matrix that comprises human matrix proteins collagen IV and at least one member selected from fibronectin, laminin, and vitronectin.

3. The method of claim 1 wherein the matrix comprises collagen IV, fibronectin, laminin, and vitronectin.

4. The method of claim 1 wherein the medium comprises gamma amino butyric acid, pipecolic acid, lithium, and optionally transforming growth factor beta.

5. The method of claim 1 wherein when the matrix comprises a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma or a matrix that comprises human matrix proteins collagen IV, fibronectin, laminin, and vitronectin, and the medium comprises salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, gamma-aminobutyric acid, pipecolic acid, lithium, and transforming growth factor beta, in sufficient amounts to maintain the human stem cells in an undifferentiated state, wherein at least 90% of the cells in culture are positive for the transcription factor Oct-4 through multiple successive culture passages.

6. An in vitro cell culture comprising in a culture vessel:

primate pluripotent stem cells;

an extracellular matrix, on which the stem cells can grow; and

a culture medium, wherein the medium comprises salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium, in sufficient amounts to maintain the human stem cells in an undifferentiated state through multiple culture passages, the medium being free of feeder cells and never having been exposed to feeder cells.

7. The cell culture of claim 6 , wherein when the matrix comprises human matrix proteins collagen IV, fibronectin, laminin, and vitronectin, and the medium comprises salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, gamma-aminobutyric acid, pipecolic acid, lithium, and transforming growth factor beta, in sufficient amounts to maintain the human stem cells in an undifferentiated state, wherein at least 90% of the cells in culture are positive for the transcription factor Oct-4 through multiple successive culture passages.

8. The cell culture of claim 6 , wherein the medium is free of products from non-human animals.

9. The cell culture of claim 6 wherein the cells are human pluripotent stem cells.

10. The cell culture of claim 6 , wherein the medium is capable of maintaining the cells through over twenty passages in culture while the cells remain undifferentiated, maintain pluripotency and maintain stable karyotype.

11. A medium comprising salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium, in sufficient amounts to maintain stem cells grown in the medium in an undifferentiated state through multiple culture passages.

12. A method for initiating a cultured line of primate pluripotent stem cells without the use of feeder cells or conditioned medium, the method comprising the step of:

plating cells from a blastocyst onto an extracellular matrix in a medium including salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium, in sufficient amounts to originate and maintain a new proliferating stem cell line in an undifferentiated state.

13. The method of claim 12 wherein the matrix comprises collagen and at least one of fibronectin, vitronectin and laminin.

14. The method of claim 12 wherein the medium comprises at least two members of gamma amino butyric acid, pipecolic acid, and lithium, and optionally transforming growth factor beta.

15. A method of increasing cloning efficiency of primate pluripotent stem cells comprising:

culturing the primate pluripotent stem cells on an extracellular matrix in a medium without feeder cells or conditioned media, the medium comprising salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, less than about 0.1 mM beta-mercaptoethanol and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium in sufficient amounts to maintain the cells in an undifferentiated state through multiple successive culture passages and such that the cloning efficiency of the pluripotent cells is increased by at least 10% compared to pluripotent stem cells cultured in the same medium, except wherein the beta-mercaptoethanol concentration is higher than about 0.1 mM.

16. A method of increasing cloning efficiency of primate pluripotent stem cells without the need for feeder cells or conditioned medium, the method comprising the step of:

culturing the primate pluripotent stem cells on a matrix that comprises a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma or a matrix that comprises human matrix proteins collagen IV, fibronectin, laminin, and vitronectin in a medium without feeder cells or conditioned media, the medium comprising salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, less than about 0.1 mM beta-mercaptoethanol, gamma-aminobutyric acid, pipecolic acid, lithium, and transforming growth factor beta, in sufficient amounts to maintain the human stem cells in an undifferentiated state, wherein at least 90% of the cells in culture are positive for the transcription factor Oct-4 through multiple successive culture passages and wherein the cloning efficiency of the pluripotent cells is increased by at least 10% compared to pluripotent stem cells cultured in the same medium, except wherein the beta-mercaptoethanol concentration is higher than about 0.1 mM.

17. A medium comprising salts, vitamins, amino acids, glucose, albumin, minerals, lipids, a transferrin or a transferrin substitute, insulin or an insulin substitute, a fibroblast growth factor, less than about 0.1 mM beta-mercaptoethanol, and at least one member selected from gamma-aminobutyric acid, pipecolic acid, and lithium, in sufficient amounts to maintain stem cells grown in the medium in an undifferentiated state through multiple culture passages.

18. The cell culture of claim 9 wherein the cells do not exhibit the sialic acid residue Neu5Gc.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 14, 2018
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045585/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2011
From: THOMSON, JAMES; LUDWIG, TENNEILLE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 026960/0403 →
Continuity (9)
Continuation In Part 12209325 · Sep 12, 2008
Continuation 11221457 · Sep 8, 2005
Continuation 12754574
Continuation In Part 12242085 · Sep 30, 2008
Continuation 11221516 · Sep 8, 2005
Provisional Application 60608040 · Sep 8, 2004
Provisional Application 60695100 · Jun 29, 2005
Provisional Application 60608040 · Sep 8, 2004
Related Publication 20100304481A1 · Dec 2, 2010